Home › Funds › Lion Point Capital, LP › IPHA

Lion Point Capital, LP position in IPHA

INNATE PHARMA S A · Health Care

Lion Point Capital, LP reported holding 81,151 shares of IPHA (INNATE PHARMA S A) in its Q2 2026 13F filing — a position valued at US$149K, representing 0.71% of its reported portfolio and ranking #33 among its reported holdings. Lion Point Capital, LP has disclosed IPHA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)81.15K sh
Reported value held$149.32K
Portfolio Weight0.71%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's IPHA position evolved

Lion Point Capital, LP first disclosed a stake in IPHA in Q4 2025 at 81,151 shares (US$142K). The position peaked in Q2 2026 at 81,151 shares, worth US$149K. Across 3 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 81,151 shares valued at US$149K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 81.15K $142.01K New
Q1 2026 81.15K $103.87K Hold
Q2 2026 81.15K $149.32K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IPHA and 13F data

IPHA (INNATE PHARMA S A) is a Health Care company. 10 other funds we track also report a position in IPHA. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IPHA

No other tracked fund reports a position in IPHA.

All IPHA fund holders →

FAQ

How long has Lion Point Capital, LP held IPHA?

Lion Point Capital, LP has disclosed IPHA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Lion Point Capital, LP's current position in IPHA?

As of Q2 2026, Lion Point Capital, LP holds 81.15K shares of IPHA (INNATE PHARMA S A), valued at $149.32K, representing 0.71% of its reported portfolio and ranking #33.

Has Lion Point Capital, LP been buying or selling IPHA?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in IPHA. The position peaked in Q2 2026 at 81.15K shares.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.